Apolo Anton Ohno, Most Decorated American Winter Athlete, Joins National Campaign To Raise Awareness Of Exercise-Induced

   Apolo Anton Ohno, Most Decorated American Winter Athlete, Joins National
      Campaign To Raise Awareness Of Exercise-Induced Bronchospasm (EIB)

Ohno Shares Personal Struggles with EIB and Invites Americans to Enter EIB All
Stars Contest

PR Newswire

FRAZER, Pa., Jan. 17, 2013

FRAZER, Pa., Jan. 17, 2013 /PRNewswire/ --Teva Respiratory has partnered with
Apolo Anton Ohno and Allergy & Asthma Network Mothers of Asthmatics (AANMA) to
launch EIB All Stars – a national campaign and contest to raise awareness of a
common, but little-known condition called exercise-induced bronchospasm (EIB).
EIB is a temporary narrowing of the airways during or after exercise that can
make it difficult to breathe. ^ Symptoms include shortness of breath, chest
tightness, trouble getting a deep breath, wheezing or noisy breathing,
coughing, and decreased exercise endurance. Diagnosed with EIB more than ten
years ago, Ohno is speaking publicly for the first time about the impact of
EIB on his short-track speed skating career and invites others to share their
EIB experiences by entering the EIB All Stars contest at www.EIBAllStars.com.

To view the multimedia assets associated with this release, please click:

(Photo: http://photos.prnewswire.com/prnh/20130117/MM40197)

"Early in my career, I had difficulty breathing during workouts and my
performance on the ice suffered," said Ohno, who was first diagnosed with EIB
in 2000 as he prepared to compete in Salt Lake City before an international
audience. "It wasn't until I was diagnosed with EIB and received the proper
treatment that I was able to reach my peak performance. I hope that by
bringing my experience to the forefront, I can encourage others with EIB to
seek out a diagnosis and treatment strategy so that they too can pursue their

EIB stories can be submitted at www.EIBAllStars.com. The contest is open to
United States citizens residing in the contiguous 48 states, or District of
Columbia, who are ages 18 years or older. Contest entrants must have been
diagnosed with EIB or be submitting on behalf of a family member diagnosed
with EIB. Entries may be submitted now through February 18, 2013 at 11:59 p.m.

The finalists will be selected by a panel of judges and their stories will be
posted to the campaign website. The public can then vote online for the most
inspirational story. The finalist receiving the most votes will win a trip for
two to Los Angeles for a getaway weekend that includes dinner with Ohno.

EIB All Stars is presented in partnership with AANMA, a national nonprofit
patient advocacy organization and leader in EIB education.

"We are thrilled to be part of a campaign and contest that celebrates the men
and women who have not let EIB hinder their activities, whether that's running
a 5k, making the basketball team or keeping up with their kids on the
playground," said Nancy Sander, president and founder of AANMA, "It is our
hope that Apolo's inspiring example will motivate people experiencing EIB to
see their healthcare professional for an evaluation and diagnosis, so they may
continue to maintain a healthy and active lifestyle despite having EIB."

For more information about EIB All Stars and full contest rules and
regulations, please visitwww.EIBAllStars.com.

About Exercise-Induced Bronchospasm (EIB)
Exercise-induced bronchospasm (EIB) is a temporary narrowing of the airways
during or after exercise that can make it difficult to breathe. EIB is a
treatable condition that may be triggered by breathing in air that is cooler
and drier than the air in your lungs. Common symptoms of EIB include shortness
of breath, chest tightness, trouble getting a deep breath, wheezing or noisy
breathing, coughing, and decreased exercise endurance. ^An individual with
EIB can experience one or more of these symptoms during or immediately
following physical activity. EIB can impact exercise performance and people
with EIB may become discouraged, frustrated or embarrassed and reduce or
eliminate physical activity from their lifestyle. While the symptoms are
similar, EIB is different from asthma. EIB symptoms are temporary and
triggered only by aerobic activity, while asthma is characterized by chronic
inflammation of the large and small airways. Overall, it is estimated that EIB
affects about 80-90 percent of children and adults with asthma, and an
estimated over 30 million people in the United States.

About Apolo Anton Ohno
Apolo Anton Ohno is the most decorated American winter athlete of all-time. He
was the youngest-ever U.S. short-track speed skating National Champion at the
age of 14 and went on to become a 12-time National Champion. He is the top
American in the sport and the face of the short-track speed skating globally.
He is one of only four Americans to have won three medals in a single winter
international games. Since making history on the ice in Vancouver in 2010,
Ohno has transitioned his athleticism to competing in and winning one of
America's most watched reality shows, ABC's "Dancing with the Stars," with his
then partner, Julianne Hough. Their performances during Season 4 of the hit
reality show remain some of the most talked about performances in the show's
long-standing history, earning him the opportunity to compete in the first
"All-Star Cast" of "Dancing with the Stars" in the fall of 2012. Ohno finished
in the Top 5 in 2012 of "Dancing with the Stars – All Stars." His speaking
skills have earned him notoriety in broadcasting, most recently as a reporter
for NBC during the summer of 2012 in London. A professional speaker and The
New York Times best-selling author of the book, "Zero Regrets," Ohno travels
the globe delivering his "Zero Regrets" presentation and philosophy towards
all aspects of life – to audiences around the world.

About Allergy and Asthma Network/Mothers of Asthmatics
Allergy & Asthma Network Mothers of Asthmatics (AANMA) is the leading national
nonprofit organization dedicated to ending needless death and suffering due to
asthma, allergies and related conditions. AANMA specializes in sharing
family-friendly, medically accurate information through its award-winning
publicationsAllergy & Asthma Todaymagazine andThe MA Reportnewsletter, its
website at www.aanma.organd numerous community outreach programs. Follow
AANMA on Facebook atwww.facebook.com/AANMAand Twitter

About Teva Respiratory
Teva Respiratory is the U.S.-based respiratory subsidiary of Teva
Pharmaceutical Industries Ltd. (NYSE: TEVA). Teva Pharmaceutical Industries
Ltd., headquartered in Israel, is a leading global pharmaceutical company and
the world's largest generic drug maker. Teva has a global product portfolio
of more than 850 medicines and a direct presence in approximately 60
countries. The company is committed to increasing access to high quality
healthcare by developing, manufacturing and marketing generic products;
innovative and specialty pharmaceuticals; and active pharmaceutical

Teva's Safe Harbor Statement under the U.S. Private Securities Litigation
Reform Act of 1995:

The following discussion and analysis contains forward-looking statements,
which express the current beliefs and expectations of management. Such
statements involve a number of known and unknown risks and uncertainties that
could cause our future results, performance or achievements to differ
significantly from the results, performance or achievements expressed or
implied by such forward-looking statements. Important factors that could cause
or contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products, competition from
the introduction of competing generic equivalents and due to increased
governmental pricing pressures, the effects of competition on sales of our
innovative medicines, especially Copaxone^® (including competition from
innovative orally-administered alternatives as well as from potential generic
equivalents), potential liability for sales of generic medicines prior to a
final resolution of outstanding patent litigation, including that relating to
our generic version of Protonix^®, the extent to which we may obtain U.S.
market exclusivity for certain of our new generic medicines, the extent to
which any manufacturing or quality control problems damage our reputation for
high quality production and require costly remediation, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), our ability to achieve expected results through our
innovative R&D efforts, dependence on the effectiveness of our patents and
other protections for innovative medicines, intense competition in our
specialty pharmaceutical businesses, uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based medicines, our potential exposure to product liability
claims to the extent not covered by insurance, any failures to comply with the
complex Medicare and Medicaid reporting and payment obligations, our exposure
to currency fluctuations and restrictions as well as credit risks, the effects
of reforms in healthcare regulation and pharmaceutical pricing and
reimbursement, adverse effects of political instability and adverse economic
conditions, major hostilities or acts of terrorism on our significant
worldwide operations, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, interruptions in our supply
chain or problems with our information technology systems that adversely
affect our complex manufacturing processes, the impact of continuing
consolidation of our distributors and customers, the difficulty of complying
with U.S. Food and Drug Administration, European Medicines Agency and other
regulatory authority requirements, potentially significant impairments of
intangible assets and goodwill, potential increases in tax liabilities
resulting from challenges to our intercompany arrangements, the termination or
expiration of governmental programs or tax benefits, any failure to retain key
personnel or to attract additional executive and managerial talent,
environmental risks, and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2011 and in our other filings
with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking
statements speak only as of the date on which they are made, and we undertake
no obligation to update any forward-looking statements or other information
contained in this report, whether as a result of new information, future
events or otherwise.

SOURCE Teva Respiratory

Website: http://www.TevaRespiratory.com
Contact: Shannon Oates-Rivera, Teva Pharmaceuticals, +1-610-318-0512,
shannon.oates-rivera@tevapharm.com; Gary Fitzgerald, Allergy & Asthma Network
Mothers of Asthmatics, +1-703-641-9595, gfitzgerald@aanma.org
Press spacebar to pause and continue. Press esc to stop.